Total Payments
$324,344
2024 Payments
$42,000
Companies
26
Transactions
175
Medicare Patients
21,753
Medicare Billing
$4.9M
Payment Breakdown by Category
Research$316,001 (97.4%)
Consulting$4,500 (1.4%)
Food & Beverage$3,071 (0.9%)
Travel$659.71 (0.2%)
Gifts$101.04 (0.0%)
Education$11.07 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $316,001 | 23 | 97.4% |
| Consulting Fee | $4,500 | 1 | 1.4% |
| Food and Beverage | $3,071 | 143 | 0.9% |
| Travel and Lodging | $659.71 | 3 | 0.2% |
| Gift | $101.04 | 4 | 0.0% |
| Education | $11.07 | 1 | 0.0% |
Payments by Type
Research
$316,001
23 transactions
General
$8,343
152 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $188,379 | 14 | $0 (2024) |
| Hexal AG | $73,101 | 5 | $0 (2024) |
| Allergan, Inc. | $60,449 | 23 | $0 (2021) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $758.54 | 44 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $318.76 | 22 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $197.02 | 8 | $0 (2023) |
| Bausch & Lomb Americas Inc. | $185.02 | 9 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $144.49 | 5 | $0 (2024) |
| Aerie Pharmaceuticals, Inc. | $142.52 | 7 | $0 (2021) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $90.75 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $42,000 | 18 | Genentech, Inc. ($33,593) |
| 2023 | $96,526 | 29 | Genentech, Inc. ($95,997) |
| 2022 | $124,186 | 30 | Hexal AG ($65,002) |
| 2021 | $467.02 | 31 | SUN PHARMACEUTICAL INDUSTRIES INC. ($160.35) |
| 2020 | $369.48 | 18 | Allergan, Inc. ($114.80) |
| 2019 | $376.26 | 27 | Novartis Pharmaceuticals Corporation ($144.40) |
| 2018 | $43,044 | 17 | Allergan Inc. ($42,907) |
| 2017 | $17,375 | 5 | Allergan Inc. ($17,345) |
All Payment Transactions
175 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Ophthalmology | ||||||
| 12/17/2024 | Genentech, Inc. | — | — | Cash or cash equivalent | $6,548.00 | Research |
| Study: Faricimab for Under represented Patients with DME | ||||||
| 11/08/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug) | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: Ophthalmology | ||||||
| 10/24/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $27.39 | General |
| Category: Ophthalmology | ||||||
| 10/23/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Dry eyes | ||||||
| 10/05/2024 | Bausch & Lomb Americas Inc. | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: Ophthalmology | ||||||
| 09/18/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 09/11/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $25.64 | General |
| Category: Ophthalmology | ||||||
| 07/22/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: Ophthalmology | ||||||
| 06/25/2024 | Genentech, Inc. | — | — | Cash or cash equivalent | $17,190.00 | Research |
| Study: Faricimab for Under represented Patients with DME | ||||||
| 05/23/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Dry eyes | ||||||
| 05/08/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $26.11 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/02/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: Ophthalmology | ||||||
| 04/30/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Ophthalmology | ||||||
| 03/21/2024 | Genentech, Inc. | — | — | Cash or cash equivalent | $9,855.00 | Research |
| Study: Faricimab for Under represented Patients with DME | ||||||
| 03/18/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Ophthalmology | ||||||
| 01/25/2024 | Hexal AG | — | — | Cash or cash equivalent | $8,099.12 | Research |
| Study: CSOK583A12301 | ||||||
| 01/18/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: Ophthalmology | ||||||
| 12/14/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $17.67 | General |
| 11/30/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $25.85 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/26/2023 | Sun Pharmaceutical Industries Inc. | Cequa (Drug) | Food and Beverage | In-kind items and services | $33.72 | General |
| Category: Ophthalmology | ||||||
| 10/18/2023 | Sun Pharmaceutical Industries Inc. | Cequa (Drug) | Food and Beverage | In-kind items and services | $5.59 | General |
| Category: Ophthalmology | ||||||
| 10/16/2023 | Bausch & Lomb Americas Inc. | — | Food and Beverage | In-kind items and services | $20.71 | General |
| 09/21/2023 | Sun Pharmaceutical Industries Inc. | Cequa (Drug) | Food and Beverage | In-kind items and services | $31.05 | General |
| Category: Ophthalmology | ||||||
| 08/29/2023 | Bausch & Lomb Americas Inc. | PROLENSA (Drug) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Faricimab for Under represented Patients with DME | Genentech, Inc. | $129,590 | 9 |
| CSOK583A12301 | Hexal AG | $73,101 | 5 |
| FARICIMAB FOR UNDER REPRESENTED PATIENTS WITH DME | Genentech, Inc. | $58,776 | 4 |
| A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration | Allergan Inc. | $44,706 | 2 |
| Phase 2 - Evaluation of Abicipar Pegol in Patients with nAMD 1771-201-008 | Allergan Inc. | $5,339 | 2 |
| EVALUATION OF SAFETY AND SYSTEMIC PHARMACOKINETICS AFTER SINGLE AND REPEAT DOSES OF ABICIPAR PEGOL AGN-150998 INTRAVITREAL INJECTIONS IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DENGENERATION | Allergan Inc. | $4,489 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 4,594 | 11,138 | $2.9M | $1.1M |
| 2022 | 25 | 6,604 | 15,991 | $4.2M | $1.5M |
| 2021 | 26 | 5,717 | 16,113 | $3.7M | $1.3M |
| 2020 | 22 | 4,838 | 14,245 | $2.9M | $968,906 |
Total Patients
21,753
Total Services
57,487
Medicare Billing
$4.9M
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 33 | 456 | $894,672 | $316,459 | 35.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 292 | 1,515 | $609,932 | $151,073 | 24.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 415 | 1,378 | $220,560 | $110,801 | 50.2% |
| 92134 | Imaging of retina | Office | 2023 | 933 | 2,532 | $251,208 | $92,093 | 36.7% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 253 | 1,216 | $182,400 | $89,619 | 49.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 482 | 662 | $160,129 | $73,012 | 45.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 220 | 723 | $99,774 | $57,325 | 57.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 240 | 304 | $62,696 | $33,168 | 52.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 211 | 223 | $60,809 | $28,058 | 46.1% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 681 | 1,119 | $111,900 | $24,122 | 21.6% |
| 92250 | Photography of the retina | Office | 2023 | 506 | 617 | $93,881 | $19,999 | 21.3% |
| 67113 | Complex repair of detached retina and drainage of eye fluid between lens and retina | Facility | 2023 | 15 | 15 | $48,250 | $17,485 | 36.2% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 23 | 23 | $40,986 | $14,611 | 35.6% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 100 | 100 | $24,400 | $12,582 | 51.6% |
| 92242 | Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | Office | 2023 | 24 | 26 | $13,780 | $6,357 | 46.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 39 | 39 | $12,246 | $5,270 | 43.0% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 40 | 70 | $13,726 | $2,910 | 21.2% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 17 | 46 | $5,060 | $2,597 | 51.3% |
| 67500 | Injection of drug into cavity behind eye | Facility | 2023 | 53 | 53 | $9,116 | $1,453 | 15.9% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 17 | 21 | $2,100 | $274.00 | 13.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 38 | 486 | $953,532 | $348,857 | 36.6% |
| 67028 | Injection of drug into eye | Office | 2022 | 339 | 1,860 | $751,248 | $184,724 | 24.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 567 | 1,837 | $293,962 | $145,327 | 49.4% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 701 | 1,235 | $336,169 | $142,067 | 42.3% |
| 92134 | Imaging of retina | Office | 2022 | 1,210 | 3,375 | $334,479 | $119,973 | 35.9% |
About Dr. Peter Win, MD
Dr. Peter Win, MD is a Ophthalmology healthcare provider based in Arcadia, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124040209.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Win, MD has received a total of $324,344 in payments from pharmaceutical and medical device companies, with $42,000 received in 2024. These payments were reported across 175 transactions from 26 companies. The most common payment nature is "" ($316,001).
As a Medicare-enrolled provider, Win has provided services to 21,753 Medicare beneficiaries, totaling 57,487 services with total Medicare billing of $4.9M. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Arcadia, CA
- Active Since 07/24/2006
- Last Updated 06/25/2019
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1124040209
Products in Payments
- VABYSMO (Drug) $58,776
- Cequa (Drug) $591.63
- XIIDRA (Drug) $226.33
- ACTHAR (Biological) $197.02
- OZURDEX (Drug) $123.53
- DUREZOL (Drug) $123.17
- PROLENSA (Drug) $120.62
- EYLEA (Biological) $118.64
- rhopressa (Drug) $87.69
- XELPROS (Drug) $81.21
- BROMSITE (Drug) $66.63
- None Specified (Medical Supply) $56.04
- Flarex (Drug) $46.94
- DURYSTA (Drug) $45.00
- MIEBO (Drug) $44.76
- SUSVIMO (Drug) $43.57
- Vabysmo (Drug) $41.69
- Rocklatan (Drug) $40.75
- TYRVAYA (Drug) $33.99
- Monaco (Device) $33.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Arcadia
Kenneth Lu, Md, MD
Ophthalmology — Payments: $25,142
Ophthalmology $25,142
Dr. Badrudin Kurwa, Md, MD
Ophthalmology — Payments: $21,050
Ophthalmology $21,050
Vikas Chopra, M.d, M.D
Ophthalmology — Payments: $8,746
Ophthalmology $8,746
Dr. Lilit Minasyan
Ophthalmology — Payments: $4,580
Ophthalmology $4,580
Morgan Huang, Md, MD
Ophthalmology — Payments: $1,874
Ophthalmology $1,874
John Beauclair, M.d, M.D
Ophthalmology — Payments: $1,139
Ophthalmology $1,139